PaxMedica to discuss significance of Phase 3 study results Interview to be webcast on Tuesday, August 15, 2023, at 10:30 am ET TARRYTOWN, NY, August 8, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) … Continue reading “PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study”
Breaking News
Breaking News
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE,…
August 8, 2023
Breaking News
Titan NRG, Inc. (TTNN) Acquires New Equipment
TUCSON, AZ, August 7, 2023 – Titan NRG, Inc. (OTC PINK:TTNN) (“Titan NRG”) a leader…
August 7, 2023